SERPINE1, serpin family E member 1, 5054

N. diseases: 770; N. variants: 23
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Plasminogen Activator Inhibitor-1 Deficiency
0.700 CausalMutation disease CLINVAR Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. 21486382 2011
Plasminogen Activator Inhibitor-1 Deficiency
0.700 GermlineCausalMutation disease ORPHANET Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. 9207454 1997
Plasminogen Activator Inhibitor-1 Deficiency
0.700 CausalMutation disease CLINVAR Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. 1435917 1992
Plasminogen Activator Inhibitor-1 Deficiency
0.700 Biomarker disease CTD_human
Plasminogen Activator Inhibitor-1 Deficiency
0.700 Biomarker disease GENOMICS_ENGLAND
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Collectively, our findings provide support that PAI-1 contributes to the development of inflammation in perirenal fat and correlates with the development of diabetic nephropathy in HFD-induced obesity. 30532990 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Addition of waist circumference to the models either decreased or nullified the contribution of PAI-1act to BP and hypertension development. 31356402 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE Hypertension (odds ratio [OR] = 1.953, p = 0.020), tHcy (OR = 1.059, p = 0.029), thyroid-stimulating hormone (OR = 0.876, p = 0.039), and the PAI-1 genotype dominant allele model (OR = 1.748, p = 0.047) were associated with IS by multivariate analysis. 30160528 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE These results demonstrates that hypertension and insulin resistance induced by COC is associated with increased cardiac RAS and PAI-1 gene expression, which is likely to be through corticosterone-dependent but not aldosterone-dependent mechanism. 26934364 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE The most significant result among all univariate and multivariate tests performed in this study was the heterogeneity of correlation between PAI-1 and mean arterial pressure at rs10738554, near SLC24A2, a gene previously associated with high blood pressure in African Americans. 28408189 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE We observed significantly lower concentration of PAI-1:Ag in DF patients treated for hypertension as compared to patients without hypertension. 28193577 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Although Angiotensin II-induced hypertension was blunted in PAI-1<sup>-/-</sup> mice, cardiac hypertrophy was accelerated. 28588076 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group BEFREE Analysis using categorical PAI-1 (in tertiles) showed that participants in the highest tertile (≥58 ng/ml) had 63% increased risk for hypertension [OR = 1.63 (1.12-2.37)] compared with those in the lowest tertile (<33 ng/ml). 28379891 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 AlteredExpression group BEFREE A model with components of MetS explained only 12% of variability on PAI-1 levels (<i>R</i><sup>2</sup> = 0.12; <i>p</i> = 0.001), with <i>β</i> = 0.18 (<i>p</i> = 0.03) for hypertension, <i>β</i> = -0.16 (<i>p</i> = 0.05) for NL HDL-c, and <i>β</i> = 0.15 (<i>p</i> = 0.05) for NL triglycerides.<i>Conclusion</i>. 28271069 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy. 26616527 2016
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Therapeutic disease RGD Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats. 26712211 2016
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 AlteredExpression group BEFREE The presence of type 2 diabetes associated with 3.2-fold increased PAI-1 expression (adjusted p=0.033), while the presence of hypertension associated with about 50% reduction of IL-8 and TIMP-1. 25496999 2015
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE A meta-analysis was conducted to investigate the association between 4 G/5 G variants in the PAI-1 gene and DN susceptibility. 24345290 2014
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Therefore, PAI-1R provides an additional therapeutic effect in slowing the progression of diabetic nephropathy via the protection of podocytes. 24443353 2014
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE Stroke prevalence and odds ratio (OR) were assessed for the following parameters: G20210A prothrombin, Arg506Glu factor V Leiden, C677T MTHFR, and 4G/5G PAI-1 polymorphisms; total number of study polymorphisms in a particular subject (genetic sum); and classic vascular risk factors of hypertension, obesity, diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertriglyceridemia, and elevated levels of low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein cholesterol. 24189452 2014
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 AlteredExpression group BEFREE Hypertension is associated with increased expression of FABP3, FAS, FN1, IL1R2, LPL, SERPINE1, TGFB1, and VCAM1 and decreased expression of SELPLG and SERPINEB2. 23337395 2014
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE Using allelic comparison (4G vs. 5G), the PAI-1 -675 4G/5G polymorphism was observed to have no significant association with diabetes (REM OR 1.07, 95% CI 0.96, 1.20), DN (REM OR 1.10, 95% CI 0.98, 1.25), DR (REM OR 1.09, 95% CI 0.97, 1.22) or diabetic CAD risk (REM OR 1.07, 95% CI 0.81, 1.42), and similar results were obtained in the dominant, recessive and co-dominant models. 24223897 2013
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE When stratified according to PAI-1 4G/5G polymorphism, there was no significant difference in all metabolic parameters among PAI-1 genotype groups in patients with HTN as well as subjects with normal blood pressure. 22613596 2012
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 Biomarker group CTD_human Vascular and thrombogenic effects of pulmonary exposure to Libby amphibole. 22352330 2012
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.600 GeneticVariation group BEFREE The functional plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism has previously been associated with hypertension. 21490692 2011